

Ametek Inc.(AME)

\$84.50 (As of 04/29/20)

Price Target (6-12 Months): **\$89.00**

Long Term: 6-12 Months

Zacks Recommendation:
Neutral

(Since: 06/10/19)

Prior Recommendation: Outperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM:B

Value: D

Growth: A

Momentum: A

Summary

AMETEK is riding on acquisition benefits. The Gatan, Telular and Spectro Scientific buyouts are driving growth in the Electronic Instruments unit. Further, positive contributions from Pacific Design Technologies acquisition are benefiting the Electromechanical unit. The company's strong product pipeline is likely to continue driving its organic growth. We believe proper execution of core growth strategies including operational excellence, global market expansion, investments in product development and strategic acquisitions will continue to aid AMETEK's top-line. However, the stock has underperformed its industry over a year. Ongoing softness in the automation market does not bode well for Electromechanical unit. Further, foreign exchange fluctuations and high goodwill associated with aggressive acquisition strategy remain risks.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$102.31 - \$54.82
20 Day Average Volume (sh)	1,449,641
Market Cap	\$19.4 B
YTD Price Change	-15.3%
Beta	1.22
Dividend / Div Yld	\$0.72 / 0.9%
Industry	Electronics - Testing Equipment
Zacks Industry Rank	Top 31% (79 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	4.9%
Last Sales Surprise	-2.7%
EPS F1 Est- 4 week change	-5.1%
Expected Report Date	05/05/2020
Earnings ESP	0.2%
P/E TTM	20.2
P/E F1	22.7
PEG F1	2.4
P/S TTM	3.8

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021					4,930 E
2020	1,205 E	1,043 E	1,134 E	1,247 E	4,633 E
2019	1,288 A	1,289 A	1,277 A	1,305 A	5,159 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$1.00 E	\$1.03 E	\$1.05 E	\$1.01 E	\$4.10 E
2020	\$1.01 E	\$0.79 E	\$0.90 E	\$0.97 E	\$3.73 E
2019	\$1.00 A	\$1.05 A	\$1.06 A	\$1.08 A	\$4.19 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 04/29/2020. The reports text is as of 04/30/2020.

Overview

AMETEK, located in Berwyn, PA, is one of the leading manufacturers of electronic appliances and electromechanical devices. AMETEK has more than 120 operating sites all over the world.

The company operates over 80 sales and service stations in North America, Europe, Asia and South America to support these operations.

AMETEK sells its products globally through two operating groups, the Electronic Instruments Group ("EIG") and the Electromechanical Group ("EMG"). The company had approximately 18,100 employees worldwide as of Dec 31, 2019.


The Electronic Instruments Group ("EIG") (64.4% of total revenue in 2019) specializes in manufacturing instruments employed for monitoring, examining, calibration and display purposes in the aerospace, power and industrial instrumentation markets. The segment is one of the leaders in many of the markets it serves, including airframe and aircraft engine sensors; process and analytical instruments; electric power generation, distribution and transmission instruments; and heavy-vehicle instrument panels.

The Electromechanical Group ("EMG") (35.6% of total revenue in 2019) produces engineered electrical connectors and electronics packaging for electronic applications in aerospace, defense, medical and industrial markets. In addition, it manufactures advanced technical motor and motion control products used in electronic data storage, medical appliances, company equipment, robotics and many other applications. It is also engaged in the production of precision motion control solutions, specialty metals and alloys; electric motors, blowers and heat exchangers.

The target customers are aerospace and defense industries, commercial and fitness equipment makers, food and beverage machine builders, and manufacturers of hydraulic pumps, industrial blowers and vacuum cleaners.

AMETEK revenues increased 6% to \$5.2 billion in 2019.

The company uses a direct sales model for the distribution of its products, which is supplemented by distributors and sales representatives as necessary. Given the scale of operations, the company has a host of competitors, including Agilent Technologies, Emerson Electric and Cognex.



Reasons To Buy:

- ▲ Considering its size and scale, AMETEK has seen pretty **strong growth** rates in the last few years due to the managements strategy of productivity improvements; increasing organic sales through global market expansion and new product development; and synergies from strategic acquisitions. This has helped Ametek build an excellent backlog that has resulted in solid performance quarter after quarter. One of the key growth strategies of AMETEK is operational excellence. AMETEK has been focusing on operational improvements and efficiencies, which will help aid both competitive and financial growth. Steps taken to implement this strategy include global sourcing, strategic procurement, lean manufacturing, value engineering, value analysis and realignment actions. In low-growth environments, Operational Excellence initiatives help the company drive significant margin expansion while also allowing it to continue to invest in key growth initiatives. Additionally, AMETEK's diversified geographic and industrial operations coupled with its highly differentiated product line indicate healthy growth prospects for the company. Both these factors cushion it against unfavorable developments in any one industry or country at a given time. With the core business remaining steady, growth initiatives are reflected quickly in top and bottom line performance.
- ▲ AMETEK supplements organic growth with **strategic acquisitions**. For this purpose, it generally looks for niche players that complement one of its many product lines or round out its portfolio. Therefore, acquisitions have mostly been small and well-managed, and incorporation issues negligible. In 2016, the company deployed around \$391.4 million in capital on five acquisitions — Brookfield Engineering Laboratories, ESP/SurgeX, Nu Instruments, HS Foils and Laserage. In 2017, AMETEK deployed around \$520 million in capital and garnered approximately \$225 million in revenues from two acquisitions – MOCON and Rauland. In early 2018, the company completed two acquisitions – FMH Aerospace and Arizona Instrument by deploying approximately \$273 million of capital. Further, AMETEK's acquisitions of Soundcom, Spectro Scientific and Motec have started aiding its top-line growth. Additionally, the company has deployed \$565 million in its recent acquisitions of Telular and Forza Silicon which are likely to strengthen its EIG division. Further, the company's latest buyout of Gatan is aiding sales growth in its EIG unit. Further, the Pacific Design Technologies buyout is contributing well to the performance of the company's EMG unit. In 2019, AMETEK spent \$1.1 billion on acquisitions.
- ▲ The company has consistently introduced **new and improved products** that added to its vastly differentiated product pipeline. Recently, Mocon launched AQUATRAN Model 3 WVTR measurement instrument. It measures the water vapor transition rate of ultra-high barrier materials. Also, Rauland launched Responder 5000 'nurse call' system. Recently, AMETEK's Zygo business launched two next-generation 3D optical profilers named - Nexview NX2 and NewView 9000 profiling instruments. The consistent product introductions generate customer loyalty and facilitate market share gains, thereby boosting revenues. New products introduced over the last three years comprised 24% of revenues. This indicates that the company is not only good at developing products but also at marketing them.

The company excels in making strategic acquisitions, driving operational efficiencies, introducing new products and taking core competencies to the global marketplace.

Reasons To Sell:

- ▼ AMETEK has a **weak balance sheet**. Total debt at the end of December 2019 was \$2.3 billion. Such high debt levels may impede sufficient cash flow generation, which is needed to meet future debt obligations. Moreover, this may keep the company from accessing the debt market and refinancing at suitable rates.
- ▼ Acquisitions are a part of AMETEK's growth strategy to supplement the top line. However, the company's inability to identify suitable acquisition candidates, unsuccessful execution and integration of new acquisitions and an increase in acquisition costs due to stiff competition could negatively impact its sales/margin performance. The large number of acquisitions increases the chances of **integration issues**.
- ▼ Its nature of business makes AMETEK vulnerable to **foreign exchange headwinds**. The company has manufacturing operations in 17 countries outside the United States and 48% of total sales come from these operations. Thus, appreciation or depreciation of the U.S. dollar versus foreign currencies could impact the company's financial results.

A weak balance sheet, foreign exchange headwinds and vulnerability to integration issues due to an extremely aggressive acquisition strategy remain major concerns.

Last Earnings Report

AMETEK Beats Q4 Earnings Estimates, Lags Revenues

AMETEK reported fourth-quarter 2019 adjusted earnings of \$1.08 per share, which beat the Zacks Consensus Estimate by 4.8% and also surpassed management's guidance of \$1.01-\$1.03. The figure improved 13% from the year-ago quarter and 1.9% sequentially.

Net sales improved 3% on a year-over-year basis and 2.2% sequentially to \$1.30 billion.

Strong performance by the company's Electronic Instruments Group (EIG) segment drove sales growth during the reported quarter. Further, positive contributions from strategic acquisitions remain a positive. Additionally, improved operational activities drove the results.

However, the top line figure fell short of the Zacks Consensus Estimate of \$1.34 billion.

Notably, the company faced weakness in its Electromechanical Group (EMG) segment during the fourth quarter, which remains a concern.

Nevertheless, the company's proper execution of the four core growth strategies of operational excellence, global market expansion, investments in product development and acquisitions are expected to continue benefiting business growth in the near term as well as the long haul.

Segments in Detail

EIG (67.5% of total sales): The company generated \$880.2 million of sales from this segment, reflecting growth of 7% from the year-ago quarter. The benefits from acquisitions of Gatan, Telular and Spectro Scientific drove year-over-year sales within this segment.

EMG (32.5% of sales): This segment generated \$424.7 million of sales in the fourth quarter, which decreased 5% on a year-over-year basis. Nevertheless, the company witnessed strong operational performance within the segment.

Operating Details

For the fourth quarter, operating expenses were \$1.01 billion, up 1.8% year over year. However, the figure contracted 60 basis points (bps) from the year-ago quarter as a percentage of net sales.

Consequently, operating margin was 22.8%, which expanded 60 bps from the year-ago reported figure.

Segment wise, operating margins for EIG and EMG were 26.1% and 19.9%, expanding 10 bps and 60 bps, respectively, on a year-over-year basis.

Balance Sheet

As of Dec 31, 2019, cash and cash equivalents were \$393.03 million, down from \$735.4 million as of Sep 30, 2019.

Further, inventories amounted to \$624.6 million at the end of the fourth quarter compared with \$623.8 million at the end of the prior quarter.

Long-term debt was \$2.3 billion, up from \$2.2 billion in the previous quarter.

Guidance

For first-quarter 2020, AMETEK expects sales to improve by a low-single digit on a year-over-year basis.

Adjusted earnings are anticipated to be \$1.01-\$1.04 per diluted share, reflecting year-over-year growth of 1-4%.

For 2020, the company anticipates total sales to improve by low-single digit from 2019.

Further, AMETEK expects adjusted earnings per share in the range of \$4.24-\$4.38 per share, reflecting growth of 1-5% from 2019.

Quarter Ending **12/2019**

Report Date	Feb 05, 2020
Sales Surprise	-2.73%
EPS Surprise	4.85%
Quarterly EPS	1.08
Annual EPS (TTM)	4.19

Recent News

On **Mar 23, 2020**, AMETEK completed the sale of the Reading Alloys business to Kymera International in an all-cash transaction valued at \$250 million.

On **Feb 24, 2020**, AMETEK revealed that it is gaining traction among health researchers on the back of its Gatan buyout. Notably, K3 camera of Gatan is being used by the researchers at the University of Texas at Austin and the National Institutes of Health to map a part of the novel coronavirus called the spike protein.

On **Feb 12, 2020**, AMETEK's Board of Directors approved a hike of 29% in the quarterly dividend which now stands at 18 cents per share. Notably, the dividend is applicable for the shareholders of the record as for Mar 13, 2020 which will be paid on Mar 31, 2020.

On **Feb 5, 2020**, AMETEK acquired IntelliPower which offers ruggedized solutions including uninterruptible power systems, external battery packs, power distribution units and power conditioners. The latest buyout expands the company's Electronic Instruments Group (EIG) segment.

On **Oct 31, 2019**, AMETEK acquired Gatan which is a manufacturer of instrumentation and software used to enhance and extend the operation and performance of electron microscopes. This will strengthen AMETEK's Electronic Instruments Group.

Valuation

AMETEK shares are down 15.5% in the year-to-date period and 2.4% over the trailing 12-month period. Stocks in the Zacks sub-industry and the Zacks Computer & Technology sector are down 9.2% and 2% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry is down 1.5% and the sector is up 6.9%.

The S&P 500 index is down 8.8% in the year-to-date period but up 0.2% in the past year.

The stock is currently trading at 21.9X forward 12-month earnings, which compares to 23.82X for the Zacks sub-industry, 23.06X for the Zacks sector and 20.81X for the S&P 500 index.

Over the past five years, the stock has traded as high as 28.65X and as low as 13.45X, with a 5-year median of 20.63X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$89 price target reflects 23.06X forward 12-month earnings.

The table below shows summary valuation data for AME

Valuation Multiples - AME					
		Stock	Sub-Industry	Sector	S&P 500
P/E F 12M	Current	21.9	23.82	23.06	20.81
	5-Year High	28.65	26.26	23.06	20.81
	5-Year Low	13.45	18.3	16.71	15.19
	5-Year Median	20.63	22.02	19.23	17.44
EV/Sales TTM	Current	4.12	4.12	3.92	2.92
	5-Year High	4.88	4.92	4.44	3.45
	5-Year Low	2.91	2.45	2.58	2.16
	5-Year Median	3.92	4.08	3.57	2.82
EV/EBITDA TTM	Current	14.38	16.46	11.38	10.76
	5-Year High	19.52	19.06	12.85	12.87
	5-Year Low	10.37	8.83	7.56	8.27
	5-Year Median	15.5	14.98	10.62	10.78

As of 04/29/2020

Industry Analysis Zacks Industry Rank: Top 31% (79 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
Agilent Technologies, Inc. (A)	Neutral	3
Advanced Energy Industries, Inc. (AEIS)	Neutral	4
Cognex Corporation (CGNX)	Neutral	3
Emerson Electric Co. (EMR)	Neutral	4
Itron, Inc. (ITRI)	Neutral	3
Kemet Corporation (KEM)	Neutral	4
Methode Electronics, Inc. (MEI)	Neutral	3
Jabil, Inc. (JBL)	Underperform	4

Industry Comparison Industry: Electronics - Testing Equipment				Industry Peers		
	AME	X Industry	S&P 500	A	AEIS	ITRI
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	4	3
VGM Score	B	-	-	F	D	C
Market Cap	19.37 B	10.56 B	20.82 B	24.38 B	2.29 B	3.01 B
# of Analysts	9	5	14	8	5	5
Dividend Yield	0.85%	0.51%	2.07%	0.91%	0.00%	0.00%
Value Score	D	-	-	F	D	C
Cash/Price	0.02	0.06	0.06	0.05	0.18	0.06
EV/EBITDA	15.26	17.65	12.12	20.26	25.20	15.73
PEG Ratio	2.33	1.66	2.51	NA	NA	1.02
Price/Book (P/B)	3.78	4.45	2.74	5.03	3.37	3.72
Price/Cash Flow (P/CF)	16.15	18.37	11.23	19.85	19.98	11.80
P/E (F1)	22.50	25.50	19.26	26.66	23.84	25.50
Price/Sales (P/S)	3.75	3.86	2.16	4.66	2.90	1.20
Earnings Yield	4.41%	3.93%	5.03%	3.75%	4.19%	3.93%
Debt/Equity	0.44	0.37	0.72	0.37	0.61	1.25
Cash Flow (\$/share)	5.23	3.96	7.01	3.96	2.98	6.39
Growth Score	A	-	-	F	D	D
Hist. EPS Growth (3-5 yrs)	11.36%	12.32%	10.88%	12.32%	14.90%	39.54%
Proj. EPS Growth (F1/F0)	-11.08%	-5.92%	-6.94%	-5.06%	2.46%	-10.96%
Curr. Cash Flow Growth	23.89%	9.31%	5.92%	9.85%	-35.66%	7.46%
Hist. Cash Flow Growth (3-5 yrs)	10.17%	9.18%	8.55%	-2.46%	8.19%	9.18%
Current Ratio	1.42	1.64	1.23	1.64	2.71	1.49
Debt/Capital	30.75%	26.93%	43.90%	26.93%	37.83%	55.56%
Net Margin	16.70%	14.59%	11.15%	14.59%	8.23%	1.96%
Return on Equity	20.14%	17.53%	16.47%	20.49%	13.49%	17.47%
Sales/Assets	0.56	0.57	0.54	0.57	0.65	0.93
Proj. Sales Growth (F1/F0)	-10.19%	-4.12%	-1.52%	-0.27%	51.79%	-4.12%
Momentum Score	A	-	-	B	D	B
Daily Price Chg	4.63%	3.82%	2.91%	4.33%	14.52%	8.41%
1 Week Price Chg	-4.05%	-0.02%	-1.74%	-4.78%	-8.50%	6.85%
4 Week Price Chg	21.04%	24.55%	21.33%	14.22%	35.02%	46.63%
12 Week Price Chg	-15.53%	-11.61%	-16.28%	-7.31%	-19.12%	-9.88%
52 Week Price Chg	-2.15%	-0.27%	-7.57%	1.61%	4.36%	44.58%
20 Day Average Volume	1,449,641	1,684,846	2,658,107	2,007,084	277,422	233,099
(F1) EPS Est 1 week change	-0.03%	0.00%	0.00%	0.08%	0.00%	-3.84%
(F1) EPS Est 4 week change	-5.09%	-6.57%	-6.32%	-8.06%	-27.21%	-16.21%
(F1) EPS Est 12 week change	-14.57%	-14.57%	-12.93%	-13.47%	-25.97%	-18.21%
(Q1) EPS Est Mthly Chg	-1.86%	-5.82%	-11.84%	-12.24%	-32.37%	-81.55%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	D
Growth Score	A
Momentum Score	A
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.